Search

HRSA Extends Small Health Care Provider Quality and Delta States Network Programs

HRSA has issued a notice extending two grant programs for rural healthcare providers. The Small Health Care Provider Quality Improvement Program receives a 1-year extension for 21 award recipients (HRSA-22-093 cohort), while the Delta States Network Development Program extends 12 award recipients (HRSA-23-031 cohort). Total funding amounts to $15,928,583 for the period August 1, 2026, through July 31, 2027.

Projected Reality variance application, FDA, California, Apr 8

Projected Reality variance application, FDA, California, Apr 8

CMS Issues Guidance on New Medicaid and CHIP Funding Limits for Noncitizens

CMS issued guidance implementing new limits on federal Medicaid and CHIP matching funds for certain noncitizens under Public Law 119-21 Section 71109. States must implement system changes by October 1, 2026, including updates to eligibility systems, applications, verification, and claims processing. Exceptions exist for emergency medical conditions and coverage of lawfully residing children and pregnant women.

Center for Scientific Review Notice of Closed Meetings

The NIH Center for Scientific Review announces five closed meetings scheduled for May 1-4, 2026. These virtual meetings will review grant applications related to clinical neuroscience, hepatitis C vaccines, endocrinology, CTSA programs, and mental health conditions. Meetings are closed under the Federal Advisory Committee Act due to confidential trade secrets and personal privacy considerations.

Center for Scientific Review Notice of Closed Meetings

NIH Center for Scientific Review announces two closed virtual meetings scheduled for May 1, 2026. The meetings will review and evaluate grant applications for career development awards in social and community influences research, and chemical countermeasures against the nervous system. Both meetings are closed to the public under the Federal Advisory Committee Act to protect confidential trade secrets and personal information.

National Human Genome Research Institute Amends Meeting Notice

The National Human Genome Research Institute has amended a prior Federal Register meeting notice to modify the schedule for the National Advisory Council for Human Genome Research meeting. The open session is moved to May 18, 2026 from 10:00 a.m. to 5:00 p.m., with the closed session moved to May 19, 2026 from 10:00 a.m. to 1:00 p.m. A videocast link has also been added for the open session.

Interagency Autism Coordinating Committee Meeting Notice

NIH announces the Interagency Autism Coordinating Committee (IACC) will hold an open hybrid meeting on April 28, 2026, from 9:00 a.m. to 5:00 p.m. ET at the NIH campus in Bethesda, MD. The meeting will discuss committee business, updates, and autism research and services activities. Public comments are accepted through April 14, 2026.

Medicare Advantage and Part D Program Changes for Contract Year 2027

CMS has published a final rule implementing comprehensive changes to Medicare Advantage (Part C), Medicare Prescription Drug Benefit (Part D), and Medicare cost plan regulations for contract year 2027. The rule codifies Inflation Reduction Act changes including the sunset of the Coverage Gap Discount Program and implementation of the new Manufacturer Discount Program, along with updates to Star Ratings, marketing standards, enrollment processes, and special needs plan requirements. The regulations are effective June 1, 2026 and apply to coverage beginning January 1, 2027.

CDER Interim Response Letter to Age Reversal Unity

FDA CDER issued an interim response letter to Age Reversal Unity regarding submission FDA-2025-P-4985, a Pre-Request for Designation (Pre-IND or similar drug development query). The letter provides preliminary feedback or requests additional information but does not constitute a final regulatory determination. The company must address agency concerns before a final response is issued.

FDA Issues Priority Review Voucher for LOARGYS (pegzilarginase-nbln)

The FDA announced issuance of a priority review voucher to Immedica Pharma AB for LOARGYS (pegzilarginase-nbln), approved February 23, 2026. The drug treats hyperargininemia in adults and pediatric patients 2 years and older with Arginase 1 Deficiency. The voucher was awarded under section 529 of the FD&C Act for rare pediatric disease products meeting specified criteria.